Adeno-Associated Virus (AVV) Vectors in Gene Therapy Market Report 2026

The adeno-associated virus (avv) vectors in gene therapy market size has grown rapidly in recent years. It will grow from $3.16 billion in 2025 to $3.7 billion in 2026 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be attributed to advancements in viral vector safety, rare genetic disorder research, clinical gene therapy success, regulatory approvals, academic research investments.

The adeno-associated virus (avv) vectors in gene therapy market size is expected to see rapid growth in the next few years. It will grow to $6.99 billion in 2030 at a compound annual growth rate (CAGR) of 17.2%. The growth in the forecast period can be attributed to commercial gene therapy launches, scalable vector production demand, precision medicine expansion, orphan drug incentives, global clinical trial growth. Major trends in the forecast period include expansion of gene augmentation therapies, rising demand for rare disease gene treatments, growth of in vivo gene delivery, increased commercial-scale vector manufacturing, focus on long-term therapeutic durability.

The growing emphasis on gene-based therapies is expected to drive the expansion of adeno-associated virus (AAV) vectors in the gene therapy market in the coming years. Gene-based therapies are treatments that alter or manipulate genes to prevent, treat, or cure diseases at the molecular level. Progress in genetic research is fueling the increasing focus on developing gene-based therapies, as it improves the accuracy and effectiveness of gene editing methods. Adeno-associated virus (AAV) vectors in gene therapy support the development of gene-based therapies by delivering therapeutic genes safely and efficiently into target cells, due to their low immunogenicity and capacity for long-term gene expression. For example, in 2023, according to IQVIA, a US-based provider of advanced analytics and technology solutions for the life sciences industry, global spending on cell and gene therapies reached $5.9 billion, marking a 38% increase from 2022. Consequently, the growing emphasis on developing gene-based therapies is driving the growth of the adeno-associated virus (AAV) vectors market.

Major companies operating in the adeno-associated virus (AAV) vectors in the gene therapy market are emphasizing advanced innovation, such as customized vector diversity for assay adaptability to enhance target tissue precision, increase therapeutic effectiveness, and accelerate the creation of personalized gene therapies across multiple indications. Customized vector diversity for assay adaptability refers to employing various AAV serotypes or constructs to support different analytical tests and therapeutic applications. For example, in May 2024, Charles River Laboratories, a US-based pharmaceutical company, launched new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV). These materials aim to meet the expanding requirements of cell and gene therapy (CGT) development. The portfolio enables a smoother transition from early-stage research to GMP-grade production and helps standardize processes while improving consistency in viral vector manufacturing. This launch addresses a significant challenge in scaling CGT programs toward clinical and commercial readiness.

In March 2023, Ginkgo Bioworks, a US-based biotechnology company, acquired StrideBio's AAV capsid discovery and engineering platform assets for an undisclosed sum. Through this acquisition, Ginkgo Bioworks seeks to strengthen its end-to-end research and development capabilities in gene therapy, with a particular focus on developing novel adeno-associated virus (AAV) capsids for enhanced gene delivery. StrideBio is a US-based biotech company specializing in engineered AAV capsids for gene therapy applications.

Major companies operating in the adeno-associated virus (avv) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2025. The regions covered in the adeno-associated virus (avv) vectors in gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adeno-associated virus (avv) vectors in gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the adeno-associated virus vectors in gene therapy market by increasing the cost of imported plasmids, cell culture materials, and viral manufacturing reagents. These impacts have been most pronounced in clinical and commercial-scale production, particularly in north america and europe where advanced inputs are globally sourced. Asia-pacific manufacturers have experienced supply chain delays. However, tariffs have accelerated domestic vector manufacturing and local bioprocess infrastructure development.

The adeno-associated virus (avv) vectors in gene therapy market research report is one of a series of new reports that provides adeno-associated virus (avv) vectors in gene therapy market statistics, including adeno-associated virus (avv) vectors in gene therapy industry global market size, regional shares, competitors with a adeno-associated virus (avv) vectors in gene therapy market share, detailed adeno-associated virus (avv) vectors in gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the adeno-associated virus (avv) vectors in gene therapy industry. This adeno-associated virus (avv) vectors in gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Adeno-associated virus (AAV) vectors in gene therapy are sophisticated delivery systems that carry genetic material into cells to address a variety of genetic disorders. Their main objective is to achieve targeted, long-term therapeutic effects by repairing or altering defective genes. AAV vectors are prized for their safety, minimal immunogenicity, and capability to deliver genes to both dividing and non-dividing cells, facilitating the creation of precise and lasting gene therapies that promote personalized medicine and revolutionize the treatment of rare and inherited diseases.

The primary types of adeno-associated virus (AAV) vectors include gene augmentation, immunotherapy, and other therapeutic approaches. Gene augmentation involves the therapeutic delivery of a functional gene into a cell to replace or compensate for a defective or missing gene. This can be carried out using various gene delivery techniques, such as ex vivo and in vivo methods. It is implemented across different operational scales, including preclinical, clinical, and commercial stages. The targeted therapeutic areas encompass genetic disorders, hematological disorders, infectious diseases, metabolic disorders, ophthalmic disorders, muscle disorders, and neurological conditions.

The adeno-associated virus (AAV) vectors in gene therapy market consists of revenues earned by entities by providing services such as gene delivery solutions, targeted therapeutic development, long-term gene expression, and treatment of genetic disorders through safe and efficient viral vector technologies. The market value includes the value of related goods sold by the service provider or included within the service offering. The adeno-associated virus (AAV) vectors in gene therapy market includes sales of viral vector delivery systems used for transporting genetic material into patient cells. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.